TROG 15.03 FASTRACK II

Primary sponsor: Trans Tasman Radiation Oncology Group (TROG)

Title

Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

Summary

Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.

Participating centres

Current participating centres (PDF)

Final accrual

71

Trial status

Closed to accrual 2 March 2020

Trial chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial contact

Annette Dempsey - TROG CRA

TROG Trial Coordinating Centre
Phone: +61 2 4014 3916
Email: FASTRACKII@trog.com.au

Further information

TROG trial 15.03 on Australian Cancer Trials website

Trial resources for TROG members

TROG 15.03 member page